

The SWI/SNF complex in cancer “ biology, biomarker

Nature Reviews Clinical Oncology

17, 435-448

DOI: [10.1038/s41571-020-0357-3](https://doi.org/10.1038/s41571-020-0357-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	LKB1 and cancer: The dual role of metabolic regulation. <i>Biomedicine and Pharmacotherapy</i> , 2020, 132, 110872.	2.5	13
2	USP24 stabilizes bromodomain containing proteins to promote lung cancer malignancy. <i>Scientific Reports</i> , 2020, 10, 20870.	1.6	8
3	Hepatocellular carcinoma: old friends and new tricks. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1898-1907.	3.2	154
5	Multiregional sequence revealed SMARCA4 R1192C mutant clones acquired EGFR C797S mutation in the metastatic site of an EGFR-mutated NSCLC patient. <i>Lung Cancer</i> , 2020, 148, 28-32.	0.9	6
6	Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. <i>JHEP Reports</i> , 2020, 2, 100167.	2.6	51
7	ARID2 Chromatin Remodeler in Hepatocellular Carcinoma. <i>Cells</i> , 2020, 9, 2152.	1.8	12
8	Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models. <i>Cancers</i> , 2020, 12, 3712.	1.7	6
9	Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL. <i>Leukemia</i> , 2020, 34, 2722-2735.	3.3	24
10	Predicting immunotherapy response through genomics. <i>Current Opinion in Genetics and Development</i> , 2021, 66, 1-9.	1.5	12
11	HELLS, a chromatin remodeler is highly expressed in pancreatic cancer and downregulation of it impairs tumor growth and sensitizes to cisplatin by reexpressing the tumor suppressor TGFBR3. <i>Cancer Medicine</i> , 2021, 10, 350-364.	1.3	24
12	The WNT/ β -catenin dependent transcription: A tissue-specific business. <i>WIREs Mechanisms of Disease</i> , 2021, 13, e1511.	1.5	52
13	The biochemical and genetic discovery of the SAGA complex. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2021, 1864, 194669.	0.9	20
14	Genome-Wide Estrogen Receptor Activity in Breast Cancer. <i>Endocrinology</i> , 2021, 162, .	1.4	28
15	Biology of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 29-56.	0.9	40
16	The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes. <i>PLoS ONE</i> , 2021, 16, e0245356.	1.1	17
17	Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers. <i>Oncogenesis</i> , 2021, 10, 3.	2.1	25
18	Molecular and Functional Links between Neurodevelopmental Processes and Treatment-Induced Neuroendocrine Plasticity in Prostate Cancer Progression. <i>Cancers</i> , 2021, 13, 692.	1.7	17
19	Acute BAF perturbation causes immediate changes in chromatin accessibility. <i>Nature Genetics</i> , 2021, 53, 269-278.	9.4	103

#	ARTICLE	IF	CITATIONS
20	Biomolecular Condensates and Cancer. <i>Cancer Cell</i> , 2021, 39, 174-192.	7.7	157
21	Transglutaminase 2 mediates transcriptional regulation through BAF250a polyamination. <i>Genes and Genomics</i> , 2021, 43, 333-342.	0.5	6
22	Evolutionary Conservation of Structural and Functional Coupling between the BRM AT-Hook and Bromodomain. <i>Journal of Molecular Biology</i> , 2021, 433, 166845.	2.0	4
23	<i>ZFTA</i> Translocations Constitute Ependymoma Chromatin Remodeling and Transcription Factors. <i>Cancer Discovery</i> , 2021, 11, 2216-2229.	7.7	32
24	Recent Advances in Understanding the Role of Autophagy in Paediatric Brain Tumours. <i>Diagnostics</i> , 2021, 11, 481.	1.3	5
26	Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1769.	1.7	21
27	Multiple interactions of the oncoprotein transcription factor MYC with the SWI/SNF chromatin remodeler. <i>Oncogene</i> , 2021, 40, 3593-3609.	2.6	14
28	Diagnostic Immunohistochemistry of Soft Tissue and Bone Tumors: An Update on Biomarkers That Correlate with Molecular Alterations. <i>Diagnostics</i> , 2021, 11, 690.	1.3	14
29	Epigenetic Dynamics in the Function of T-Lineage Regulatory Factor Bcl11b. <i>Frontiers in Immunology</i> , 2021, 12, 669498.	2.2	12
30	Deregulation of enhancer structure, function, and dynamics in acute lymphoblastic leukemia. <i>Trends in Immunology</i> , 2021, 42, 418-431.	2.9	4
31	ARID1 proteins: from transcriptional and post-translational regulation to carcinogenesis and potential therapeutics. <i>Epigenomics</i> , 2021, 13, 809-823.	1.0	12
32	Downregulation of ARID1B, a tumor suppressor in the WNT subgroup medulloblastoma, activates multiple oncogenic signaling pathways. <i>Human Molecular Genetics</i> , 2021, 30, 1721-1733.	1.4	8
33	SWI/SNF subunit BAF155 N-terminus structure informs the impact of cancer-associated mutations and reveals a potential drug binding site. <i>Communications Biology</i> , 2021, 4, 528.	2.0	5
35	Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors. <i>Acta Neuropathologica</i> , 2021, 142, 361-374.	3.9	6
36	Research on Anal Squamous Cell Carcinoma: Systemic Therapy Strategies for Anal Cancer. <i>Cancers</i> , 2021, 13, 2180.	1.7	8
38	<sc>T</sc>herapeutic targeting of chromatin: status and opportunities. <i>FEBS Journal</i> , 2022, 289, 1276-1301.	2.2	10
39	Vignettes to Illustrate the Value of Tumor Biobanks in Cancer Research in Canada. <i>Biopreservation and Biobanking</i> , 2022, 20, 75-83.	0.5	3
40	Intrinsically disordered Meningioma-1 stabilizes the BAF complex to cause AML. <i>Molecular Cell</i> , 2021, 81, 2332-2348.e9.	4.5	14

#	ARTICLE	IF	CITATIONS
41	Patent highlights February–March 2021. <i>Pharmaceutical Patent Analyst</i> , 2021, 10, 183-190.	0.4	0
42	Molecular events in neuroendocrine prostate cancer development. <i>Nature Reviews Urology</i> , 2021, 18, 581-596.	1.9	65
43	SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1176-1187.	0.5	49
44	SWI/SNF complexes as determinants of R-loop metabolism. <i>Nature Genetics</i> , 2021, 53, 940-941.	9.4	2
45	The SWI/SNF complex regulates the expression of miR-222, a tumor suppressor microRNA in lung adenocarcinoma. <i>Human Molecular Genetics</i> , 2021, 30, 2263-2271.	1.4	2
46	Potential Role of SWI/SNF Complex Subunit Actin-Like Protein 6A in Cervical Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 724832.	1.3	2
47	Epigenetic “Drivers” of Cancer. <i>Journal of Molecular Biology</i> , 2021, 433, 167094.	2.0	12
49	PHF10 subunit of PBAF complex mediates transcriptional activation by MYC. <i>Oncogene</i> , 2021, 40, 6071-6080.	2.6	9
50	Histone Modifying Enzymes as Targets for Therapeutic Intervention in Oesophageal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 4084.	1.7	0
51	Comprehensive Immunohistochemical Study of the SWI/SNF Complex Expression Status in Gastric Cancer Reveals an Adverse Prognosis of SWI/SNF Deficiency in Genomically Stable Gastric Carcinomas. <i>Cancers</i> , 2021, 13, 3894.	1.7	9
52	Binding specificity and function of the SWI/SNF subunit SMARCA4 bromodomain interaction with acetylated histone H3K14. <i>Journal of Biological Chemistry</i> , 2021, 297, 101145.	1.6	3
53	SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca ²⁺ flux to mitochondria. <i>Nature Communications</i> , 2021, 12, 5404.	5.8	20
54	Recurrent mutations in multiple components of the SWI/SNF complex in myelodysplastic syndromes and acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, , .	1.2	3
55	Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. <i>Frontiers in Oncology</i> , 2021, 11, 698192.	1.3	8
56	Î2-actin dependent chromatin remodeling mediates compartment level changes in 3D genome architecture. <i>Nature Communications</i> , 2021, 12, 5240.	5.8	31
57	Comprehensive characterization and clinical relevance of the SWI/SNF copy number aberrations across human cancers. <i>Hereditas</i> , 2021, 158, 38.	0.5	1
58	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. <i>Acta Neuropathologica</i> , 2021, 141, 281-290.	3.9	31
60	Polycomb and Trithorax Group Proteins: The Long Road from Mutations in <i>Drosophila</i> to Use in Medicine. <i>Acta Naturae</i> , 2020, 12, 66-85.	1.7	12

#	ARTICLE	IF	CITATIONS
61	The DPF Domain As a Unique Structural Unit Participating in Transcriptional Activation, Cell Differentiation, and Malignant Transformation. <i>Acta Naturae</i> , 2020, 12, 57-65.	1.7	10
62	Clinicopathological Significance of ATRX Expression in Nasopharyngeal Carcinoma Patients: A Retrospective Study. <i>Journal of Cancer</i> , 2021, 12, 6931-6936.	1.2	0
63	<i>SMARCA4</i> : Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2341-2351.	1.9	52
65	BRAF mutations in thyroid cancer. <i>Current Opinion in Oncology</i> , 2022, 34, 9-18.	1.1	28
66	Regulated splicing of large exons is linked to phase separation of vertebrate transcription factors. <i>EMBO Journal</i> , 2021, 40, e107485.	3.5	8
67	The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?. <i>Frontiers in Oncology</i> , 2021, 11, 745187.	1.3	33
68	Low expression of lncRNA SBF2AS1 regulates the miR-302b/TGFBR2 axis, promoting metastasis in laryngeal cancer. <i>Molecular Carcinogenesis</i> , 2022, 61, 45-58.	1.3	6
70	BRD9 inhibition promotes PUMA-dependent apoptosis and augments the effect of imatinib in gastrointestinal stromal tumors. <i>Cell Death and Disease</i> , 2021, 12, 962.	2.7	9
71	Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11352.	1.8	1
73	SWI/SNF Complex-deficient Undifferentiated Carcinoma of the Gastrointestinal Tract. <i>American Journal of Surgical Pathology</i> , 2022, 46, 889-906.	2.1	24
74	Relationship between cellular morphology and abnormality of SWI/SNF complex subunits in pancreatic undifferentiated carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2945-2957.	1.2	5
75	KSHV transactivator-derived small peptide traps coactivators to attenuate MYC and inhibits leukemia and lymphoma cell growth. <i>Communications Biology</i> , 2021, 4, 1330.	2.0	7
76	The SWI/SNF chromatin remodeling assemblies BAF and PBAF differentially regulate cell cycle exit and cellular invasion in vivo. <i>PLoS Genetics</i> , 2022, 18, e1009981.	1.5	18
77	Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability. <i>Cancer Research</i> , 2022, 82, 791-804.	0.4	22
78	SNF5, a core subunit of SWI/SNF complex, regulates melanoma cancer cell growth, metastasis, and immune escape in response to matrix stiffness. <i>Translational Oncology</i> , 2022, 17, 101335.	1.7	1
79	Epigenetic mechanisms of inner ear development. <i>Hearing Research</i> , 2022, 426, 108440.	0.9	5
80	Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis. <i>National Science Review</i> , 2022, 9, .	4.6	4
81	DNA Double Strand Break Repair and Its Control by Nucleosome Remodeling. <i>Frontiers in Genetics</i> , 2021, 12, 821543.	1.1	8

#	ARTICLE	IF	CITATIONS
82	BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage. <i>Oncogene</i> , 2022, 41, 1397-1409.	2.6	7
83	Rare Hereditary Gynecological Cancer Syndromes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1563.	1.8	4
84	ARID1A knockdown enhances carcinogenesis features and aggressiveness of Caco-2 colon cancer cells: An <i>in vitro</i> cellular mechanism study. <i>Journal of Cancer</i> , 2022, 13, 373-384.	1.2	10
85	The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma. <i>Cancers</i> , 2022, 14, 679.	1.7	4
86	It's all in the combination: decoding the epigenome for cancer research and diagnostics. <i>Current Opinion in Genetics and Development</i> , 2022, 73, 101899.	1.5	6
87	Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2022, 27, 501-511.	1.9	14
88	Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. <i>Journal of Clinical Oncology</i> , 2022, 40, 1552-1561.	0.8	26
89	Dedifferentiation-like tubular and solid carcinoma of the stomach shows phenotypic divergence and association with deficient SWI/SNF complex. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 771-781.	1.4	4
90	A case of endometrioid carcinoma of the uterine corpus containing an atypical high-grade component showing loss of expression of the SWI/SNF complex. <i>The Journal of the Japanese Society of Clinical Cytology</i> , 2022, 61, 48-52.	0.0	0
91	Induction of senescence-associated secretory phenotype underlies the therapeutic efficacy of PRC2 inhibition in cancer. <i>Cell Death and Disease</i> , 2022, 13, 155.	2.7	14
93	Immune Epigenetic Crosstalk Between Malignant B Cells and the Tumor Microenvironment in B Cell Lymphoma. <i>Frontiers in Genetics</i> , 2022, 13, 826594.	1.1	6
94	Unclassified Neuroendocrine Tumor with a Novel CHD4::AFF2 Fusion: Expanding the Family of AFF2-Rearranged Head and Neck Malignancies. <i>Head and Neck Pathology</i> , 2022, 16, 928-933.	1.3	3
95	Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer. <i>Nature Communications</i> , 2022, 13, 1061.	5.8	55
96	SMARCB1/INI1-deficient primary lung carcinoma with hepatic metastasis. <i>Pathology</i> , 2022, 54, 817-820.	0.3	3
97	Integrative Analyses of Genes Associated With Otologic Disorders in Turner Syndrome. <i>Frontiers in Genetics</i> , 2022, 13, 799783.	1.1	0
98	Multi-omic alterations of the SWI/SNF complex define a clinical subgroup in lung adenocarcinoma. <i>Clinical Epigenetics</i> , 2022, 14, 42.	1.8	5
99	Rare Subtype of Endometrial Cancer: Undifferentiated/Dedifferentiated Endometrial Carcinoma, from Genetic Aspects to Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3794.	1.8	5
101	Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments. <i>Biomedicines</i> , 2022, 10, 650.	1.4	24

#	ARTICLE	IF	CITATIONS
102	Emerging roles of JMJD3 in cancer. <i>Clinical and Translational Oncology</i> , 2022, 24, 1238-1249.	1.2	8
103	Prometastatic CXCR4 and Histone Methyltransferase EZH2 Are Upregulated in SMARCB1/INI1-Deficient and TP53-Mutated Poorly Differentiated Chordoma. <i>Journal of Molecular Pathology</i> , 2022, 3, 68-77.	0.5	1
104	Missense Variants Reveal Functional Insights Into the Human ARID Family of Gene Regulators. <i>Journal of Molecular Biology</i> , 2022, 434, 167529.	2.0	6
105	An Intrahepatic Cholangiocarcinoma with Focal Rhabdoid Features and SMARCA4-Deficiency. <i>International Journal of Surgical Pathology</i> , 2022, 30, 581-585.	0.4	1
106	Upregulated Expression of Actin-Like 6A is a Risk Factor Affecting the Prognosis of Pancreatic Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 9467-9475.	0.9	0
107	Prognostic biomarker SMARCC1 and its association with immune infiltrates in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2021, 21, 701.	1.8	10
108	Multiple functions of SWI/SNF chromatin remodeling complex in plant-pathogen interactions. <i>Stress Biology</i> , 2021, 1, 1.	1.5	6
109	SWI/SNF chromatin remodeling complex is required for initiation of sex-dependent differentiation in mouse germline. <i>Scientific Reports</i> , 2021, 11, 24074.	1.6	8
110	Molecular features of primary hepatic undifferentiated carcinoma. <i>Modern Pathology</i> , 2022, 35, 680-687.	2.9	3
111	Molecular Markers for Long-term Survival in Stage IIIA (N2) NSCLC Patients. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 94-104.	1.0	3
112	SMARCA4/BRG1-Deficient Sinonasal Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 1122-1130.	1.2	19
113	Role of the SWI/SNF Chromatin Remodeling Complex in Regulation of Inflammation Gene Expression. <i>Molecular Biology</i> , 2022, 56, 182-195.	0.4	2
114	Can aggressive cancers be identified by the "aggressiveness" of their chromatin?. <i>BioEssays</i> , 2022, , 2100212.	1.2	2
115	Cytomorphologic features of SMARCA4-deficient non-small cell lung carcinoma and correlation with immunohistochemical and molecular features. <i>Cancer Cytopathology</i> , 2022, 130, 620-629.	1.4	2
116	SMARCA4-Deficient Lung Carcinoma is an Aggressive Tumor Highly Infiltrated by FOXP3+ Cells and Neutrophils. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
117	Epigenetics and its therapeutic potential in colorectal cancer. <i>Epigenomics</i> , 2022, , .	1.0	4
118	Structure of human chromatin-remodelling PBAF complex bound to a nucleosome. <i>Nature</i> , 2022, 605, 166-171.	13.7	42
119	Functionalization of Nanomaterials for Skin Cancer Theranostics. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 887548.	2.0	1

#	ARTICLE	IF	CITATIONS
139	Molecular basis of epigenetic regulation in cancer diagnosis and treatment. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
140	Establishment and characterization of NCC-MRT1-C1: a novel cell line of malignant rhabdoid tumor. <i>Human Cell</i> , 0, , .	1.2	0
141	GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 11177-11186.	2.9	6
142	The SWI/SNF chromatin remodeling factor DPF3 regulates metastasis of ccRCC by modulating TGF- β 2 signaling. <i>Nature Communications</i> , 2022, 13, .	5.8	9
143	Small cell carcinoma of the ovary, hypercalcemic type. , 2023, , 109-119.		0
144	The epigenetics of aging. , 2023, , 333-358.		0
145	Epigenetic Coregulation of Androgen Receptor Signaling. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 277-293.	0.8	3
146	The <i>Drosophila</i> BEAF insulator protein interacts with the polybromo subunit of the PBAP chromatin remodeling complex. <i>G3: Genes, Genomes, Genetics</i> , 2022, 12, .	0.8	1
147	PBAF chromatin remodeler complexes that mediate meiotic transitions in mouse. <i>Development (Cambridge)</i> , 2022, 149, .	1.2	0
148	Transcriptional Regulation of Endogenous Retroviruses and Their Misregulation in Human Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10112.	1.8	9
149	TGFB2-AS1 inhibits triple-negative breast cancer progression via interaction with SMARCA4 and regulating its targets <i>TGFB2</i> and <i>SOX2</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	17
150	Histopathologically atypical astroblastoma with MN1-CXXC5 fusion transcript diagnosed by methylation classifier. <i>Archives of Community Medicine and Public Health</i> , 2022, 8, 113-117.	0.1	1
151	Primary cutaneous SMARCA4-deficient undifferentiated malignant neoplasm: first two cases with clinicopathologic and molecular comparison to eight visceral counterparts. <i>Modern Pathology</i> , 2022, 35, 1821-1828.	2.9	3
152	SWI/SNF-deficient Malignancies: Optimal Candidates for Immune-oncological Therapy?. <i>Advances in Anatomic Pathology</i> , 0, Publish Ahead of Print, .	2.4	4
153	ARID1A-dependent maintenance of H3.3 is required for repressive CHD4-ZMYND8 chromatin interactions at super-enhancers. <i>BMC Biology</i> , 2022, 20, .	1.7	7
154	Genomic regulation of transcription and RNA processing by the multitasking Integrator complex. <i>Nature Reviews Molecular Cell Biology</i> , 2023, 24, 204-220.	16.1	24
155	Molecular diagnosis and treatment of meningiomas: an expert consensus (2022). <i>Chinese Medical Journal</i> , 2022, 135, 1894-1912.	0.9	5
156	Undifferentiated Endometrial Carcinoma—Diagnostic and Therapeutic Challenges. <i>AJSP Review and Reports</i> , 2022, 27, 208-211.	0.0	0

#	ARTICLE	IF	CITATIONS
157	PBRM1 presents a potential prognostic marker and therapeutic target in duodenal papillary carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	0
160	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
162	BCL7A-containing SWI/SNF/BAF complexes modulate mitochondrial bioenergetics during neural progenitor differentiation. <i>EMBO Journal</i> , 2022, 41, .	3.5	5
163	BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma. <i>Cancer Discovery</i> , 0, , OF1-OF26.	7.7	8
164	Germline SMARCA4 Deletion as a Driver of Uterine Cancer: An Atypical Presentation. <i>JCO Precision Oncology</i> , 2022, , .	1.5	1
165	Selective advantage of epigenetically disrupted cancer cells via phenotypic inertia. <i>Cancer Cell</i> , 2023, 41, 70-87.e14.	7.7	18
166	Nuclear Actin Dynamics in Gene Expression, DNA Repair, and Cancer. <i>Results and Problems in Cell Differentiation</i> , 2022, , 625-663.	0.2	4
167	The Role of Nuclear Actin in Genome Organization and Gene Expression Regulation During Differentiation. <i>Results and Problems in Cell Differentiation</i> , 2022, , 607-624.	0.2	3
168	The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13670.	1.8	8
170	Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers. <i>Nature Communications</i> , 2022, 13, .	5.8	22
172	Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1 but choriocarcinoma?. <i>Pathology Research and Practice</i> , 2023, 241, 154269.	1.0	1
173	Congenital diaphragmatic hernia in Coffin Siris syndrome: Further evidence from two cases. <i>American Journal of Medical Genetics, Part A</i> , 0, , .	0.7	0
174	Multiprotein GLI Transcriptional Complexes as Therapeutic Targets in Cancer. <i>Life</i> , 2022, 12, 1967.	1.1	0
175	ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. <i>Nature Communications</i> , 2022, 13, .	5.8	20
176	Structure of nucleosome-bound human PBAF complex. <i>Nature Communications</i> , 2022, 13, .	5.8	11
177	Cooperation of chromatin remodeling SWI/SNF complex and pioneer factor AP-1 shapes 3D enhancer landscapes. <i>Nature Structural and Molecular Biology</i> , 2023, 30, 10-21.	3.6	26
178	Comprehensive characterization of three classes of Arabidopsis SWI/SNF chromatin remodelling complexes. <i>Nature Plants</i> , 2022, 8, 1423-1439.	4.7	19
180	The Splicing Factor PTBP1 Represses TP63 ^{Î³} Isoform Production in Squamous Cell Carcinoma. <i>Cancer Research Communications</i> , 2022, 2, 1669-1683.	0.7	0

#	ARTICLE	IF	CITATIONS
181	SMARCB1 Loss in Poorly Differentiated Chordomas Drives Tumor Progression. American Journal of Pathology, 2023, 193, 456-473.	1.9	3
182	Mechanism of action of the SWI/SNF family complexes. Nucleus, 2023, 14, .	0.6	10
183	Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma. Nature Communications, 2023, 14, .	5.8	5
184	YAP-Activated SATB2 Is a Coactivator of NRF2 That Amplifies Antioxidative Capacity and Promotes Tumor Progression in Renal Cell Carcinoma. Cancer Research, 2023, 83, 786-803.	0.4	1
185	Chromatin Dynamics: Chromatin Remodeler, Epigenetic Modification and Diseases. , 0, , .		0
186	The role of EZH1 and EZH2 in development and cancer. BMB Reports, 2022, 55, 595-601.	1.1	12
187	Epigenetically programmed resistance to chemo- and immuno-therapies. Advances in Cancer Research, 2023, , 41-71.	1.9	0
188	Type 2 transglutaminase in the nucleus: the new epigenetic face of a cytoplasmic enzyme. Cellular and Molecular Life Sciences, 2023, 80, .	2.4	5
189	Evaluation of immunotherapy efficacy in gynecologic cancer. Frontiers in Immunology, 0, 14, .	2.2	2
190	STK11 loss and SMARCB1 deficiency mutation in a dedifferentiated lung cancer patient present response to neo-adjuvant treatment with pembrolizumab and platinum doublet: A case report. Frontiers in Oncology, 0, 13, .	1.3	0
191	The Next Frontier in Sarcoma: Molecular Pathways and Associated Targeted Therapies. Cancers, 2023, 15, 1692.	1.7	0
192	The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer. Cancers, 2023, 15, 2228.	1.7	6
193	Landscape of chromatin remodeling gene alterations in endometrial carcinoma. Gynecologic Oncology, 2023, 172, 54-64.	0.6	3
195	SWI/SNF complex, promising target in melanoma therapy: Snapshot view. Frontiers in Medicine, 0, 10, .	1.2	0
196	Ovarian high-grade serous carcinoma cells with low <sc>SMARCA4</sc> expression and high <sc>SMARCA2</sc> expression contribute to platinum resistance. Journal of Pathology, 2023, 260, 56-70.	2.1	2
197	BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma. Clinical Cancer Research, 2023, 29, 1807-1821.	3.2	6
198	Bioinformatics-based analysis of the roles of sex hormone receptors in endometriosis development. International Journal of Medical Sciences, 2023, 20, 415-428.	1.1	1
199	Proximity labeling reveals a new in vivo network of interactors for the histone demethylase KDM5. Epigenetics and Chromatin, 2023, 16, .	1.8	4

#	ARTICLE	IF	CITATIONS
200	Multilevel proteomic analyses reveal molecular diversity between diffuse-type and intestinal-type gastric cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	3
201	SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities. <i>Molecular Cancer</i> , 2023, 22, .	7.9	12
202	SWI/SNF Complex Genomic Alterations as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Multiple Cancers. <i>Cancer Immunology Research</i> , 2023, 11, 646-656.	1.6	7
203	Dedifferentiated Ovarian Carcinoma with ARID1A and ARID1B Mutations: A Clinicopathological Report and Literature Review. <i>International Journal of Surgical Pathology</i> , 0, , 106689692311577.	0.4	0
204	The SMARCA4R1157W mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	3
205	GEMC1 and MCIDAS interactions with SWI/SNF complexes regulate the multiciliated cell-specific transcriptional program. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	4
206	Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion. <i>Molecular Cell</i> , 2023, 83, 1216-1236.e12.	4.5	13
207	Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective. <i>Cells</i> , 2023, 12, 952.	1.8	3
208	BCL7A is silenced by hypermethylation to promote acute myeloid leukemia. <i>Biomarker Research</i> , 2023, 11, .	2.8	0
209	Characterization of Switch/Sucrose Nonfermenting Complex Proteins and Nestin Expression in a Cohort of Pediatric Central Nervous System Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 0, Publish Ahead of Print, .	0.6	0
210	Two Cases of SMARCA4-Deficient Non-small Cell Lung Cancer (NSCLC) with Improved Performance Status (PS) after Treatment with Immune Checkpoint Inhibitors (ICIs). <i>Cureus</i> , 2023, , .	0.2	0
211	SMARCB1-Deficient Sinonasal Carcinoma: Case Report and Review of the Literature. <i>American Journal of Case Reports</i> , 0, 24, .	0.3	0
217	Case Report: Nintedanib for immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with SMARCA4-mutant NSCLC: a case report. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
223	Contrôle de la transcription. , 2023, , 117-127.		0
235	Case Report: SMARCA4 (BRG1)-deficient undifferentiated carcinoma of gallbladder with genetic analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
236	Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential. <i>Experimental and Molecular Medicine</i> , 2023, 55, 1357-1370.	3.2	15
271	The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer. <i>Cancer Treatment and Research</i> , 2023, , 211-244.	0.2	1
272	Epigenetic (De)regulation in Prostate Cancer. <i>Cancer Treatment and Research</i> , 2023, , 321-360.	0.2	0

#	ARTICLE	IF	CITATIONS
288	The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation. Cancer Gene Therapy, 0, , .	2.2	0